PL3740190T3 - Postać krystaliczna cząstek stałych kokryształu apomorfina·kwas palmitynowy - Google Patents

Postać krystaliczna cząstek stałych kokryształu apomorfina·kwas palmitynowy

Info

Publication number
PL3740190T3
PL3740190T3 PL19700411.2T PL19700411T PL3740190T3 PL 3740190 T3 PL3740190 T3 PL 3740190T3 PL 19700411 T PL19700411 T PL 19700411T PL 3740190 T3 PL3740190 T3 PL 3740190T3
Authority
PL
Poland
Prior art keywords
apomorphine
palmitic acid
crystal form
acid cocrystal
particulate crystal
Prior art date
Application number
PL19700411.2T
Other languages
English (en)
Inventor
Enrique LLAUDET CARLES
Nicolas Tesson
Montserrat TRILLA CASTAÑO
Original Assignee
Leukos Biotech, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukos Biotech, S.L. filed Critical Leukos Biotech, S.L.
Publication of PL3740190T3 publication Critical patent/PL3740190T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
PL19700411.2T 2018-01-18 2019-01-15 Postać krystaliczna cząstek stałych kokryształu apomorfina·kwas palmitynowy PL3740190T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382023 2018-01-18
PCT/EP2019/050922 WO2019141673A1 (en) 2018-01-18 2019-01-15 Apomorphine·palmitic acid cocrystal solid particle crystalline form

Publications (1)

Publication Number Publication Date
PL3740190T3 true PL3740190T3 (pl) 2025-03-24

Family

ID=61168020

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19700411.2T PL3740190T3 (pl) 2018-01-18 2019-01-15 Postać krystaliczna cząstek stałych kokryształu apomorfina·kwas palmitynowy

Country Status (18)

Country Link
US (1) US11382867B2 (pl)
EP (2) EP4509187A3 (pl)
JP (1) JP7303814B2 (pl)
KR (1) KR102956773B1 (pl)
CN (1) CN111601587B (pl)
AU (1) AU2019208396B2 (pl)
BR (1) BR112020014598A2 (pl)
CA (1) CA3088824A1 (pl)
ES (1) ES3009900T3 (pl)
FI (1) FI3740190T3 (pl)
HR (1) HRP20250184T1 (pl)
HU (1) HUE070062T2 (pl)
MX (1) MX2020007656A (pl)
PL (1) PL3740190T3 (pl)
PT (1) PT3740190T (pl)
RU (1) RU2020126518A (pl)
SI (1) SI3740190T1 (pl)
WO (1) WO2019141673A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026092665A1 (en) * 2024-10-31 2026-05-07 Alar Pharmaceuticals Inc. Apomorphine salts, their formulations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1248441A (zh) * 1998-09-23 2000-03-29 珠海经济特区生物化学制药厂 盐酸阿扑吗啡口含片及其用途
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
JP2004513899A (ja) * 2000-11-15 2004-05-13 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 抗鬱薬誘発性的機能不全のアポモルヒネによる治療
WO2004082630A2 (en) 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
WO2013183055A1 (en) * 2012-06-05 2013-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP2959904A1 (en) 2014-06-27 2015-12-30 Institut De Recerca Contra La Leucemia Josep Carreras Methods for treating, diagnosing and prognosing a haematological malignancy
MX2017008382A (es) * 2014-12-23 2018-04-30 Neuroderm Ltd Formas cristalinas de apomorfina y sus usos.

Also Published As

Publication number Publication date
BR112020014598A2 (pt) 2020-12-08
KR20200110671A (ko) 2020-09-24
SI3740190T1 (sl) 2025-03-31
CN111601587B (zh) 2024-03-05
EP3740190B1 (en) 2024-11-20
HRP20250184T1 (hr) 2025-04-11
EP3740190A1 (en) 2020-11-25
CA3088824A1 (en) 2019-07-25
FI3740190T3 (fi) 2025-02-16
JP7303814B2 (ja) 2023-07-05
US20200405648A1 (en) 2020-12-31
AU2019208396B2 (en) 2024-11-14
PT3740190T (pt) 2025-02-17
AU2019208396A1 (en) 2020-07-23
EP4509187A2 (en) 2025-02-19
EP4509187A3 (en) 2025-03-12
ES3009900T3 (en) 2025-03-31
CN111601587A (zh) 2020-08-28
KR102956773B1 (ko) 2026-04-23
RU2020126518A (ru) 2022-02-21
HUE070062T2 (hu) 2025-05-28
JP2021510687A (ja) 2021-04-30
US11382867B2 (en) 2022-07-12
MX2020007656A (es) 2020-09-18
WO2019141673A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
IL283692A (en) Novel composition
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
HUE058687T2 (hu) Azonnali elõkészítés
PL3880654T3 (pl) Związki 2-formylo-3-hydroksyfenyloksymetylowe zdolne do modulowania hemoglobiny
LT3810602T (lt) Junginiai
PL3838888T3 (pl) Triestry kwasu cykloheksanotripropionowego
EP3378505A4 (en) MATERIAL FOR THE MANUFACTURE OF ARTIFICIAL CRYSTALS
EP3808783A4 (en) Novel crosslinked alginic acid
EP3473613A4 (en) SULFONIC ACID ESTER COMPOUND AND USE THEREOF
EP3772265C0 (de) Hackvorrichtung
IL281720A (en) Hmgb1 protein derivatives for the removal of biofilms
FIC20260011I1 (fi) nirogasestaatin dihydrobromidisuolan kiteinen muoto
EP3830103C0 (en) FLUORINATED BILE ACID DERIVATIVES
IL248594B (en) Ppar gamma agonists for treatment of multiple sclerosis
HUE065134T2 (hu) Vegyületek
DK3808747T3 (da) Imidazopyridinon-forbindelse
LT3867247T (lt) Naujieji junginiai
IL280448A (en) Crystalline epinephrine malonate salt
DK3826723T3 (da) Boronsyrederivater
EP3797648A4 (en) BEDDING
IL271884B1 (en) Compounds for the reducing lipotoxic damage
ES1266784Y (es) Filtro
SI3749673T1 (sl) Kristalinična oblika biktegravir natrija
HRP20260316T1 (hr) Postupak akvakulture
EP3743035A4 (en) MICRO ENCAPSULATED ACID MATERIALS